Creative Proteomics Offers Untargeted Metabolomics Service for Academia and Various Industries
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. Creative Proteomics has deep industry and business process expertise, global resources, and a good reputation in providing contract services specialized for metabolomics.
Recently, the company announced the untargeted metabolomics service, which is a powerful tool for large-scale early phase diagnosis and discovery of new biomarkers.
Untargeted metabolomics is a study in which all detectable metabolites are identified and quantified to analyze the overall metabolic characteristics and discover the metabolic mechanism behind the phenomenon. Untargeted metabolomics, also known as discovery metabolomics, is a powerful tool for large-scale early diagnosis and discovery of new biomarkers. Compared with traditional metabolic quantitative methods, untargeted metabolomics is a high-throughput technology that can achieve more comprehensive analysis through more accurate data collection and eliminate biased research directions.
“Based on the liquid chromatography-mass spectrometry technology, almost all metabolites are qualitatively and quantitatively analyzed under certain physiological or specific conditions to discover and identify different metabolites. Our untargeted metabolome analysis platform can accurately and quickly analyze various biological samples, such as blood, urine, tissue, saliva, amniotic fluid, cells and cell fluid, etc., and small molecules covering more than 95% of the pathways in plant samples.” Commented Senior Scientist of Creative Proteomics.
“Untargeted metabolomics, to the greatest extent, reflects the multiple dynamic responses of organisms to external stimuli, pathophysiological changes and their own genetic mutations at the level of metabolites in the body.” He added.
Creative Proteomics uses LC-MS/MS to provide untargeted metabolomics services, including comprehensive metabolite identification, quantification, characterization and analysis for the medical, agricultural, food processing, and environmental testing markets. The company provides the following services:
1. Metabolic profile analysis
2. Screening for differential metabolites
3. Metabolic pathway analysis of differential metabolites
4. Discover new biomarkers
Creative Proteomics employs state-of-the-art LC-MS/MS and GC-MS/MS systems for untargeted metabolomics studies. The primary instruments include AN Sciex Qtrap 6500 Plus, AB 5600 Triple TOF, Agilent 7890-5977, Thermo TSQTM 9000.
“Creative Proteomics has deep industry and business process expertise, global resources, and good reputation in providing contract services specialized for metabolomics. Our professional team provides a broader perspective, supporting data interpretation that enables our clients to understand biological issues in-depth and promote the development of science that makes a difference in people's lives.” Said Melissa, Marketing Manager of Creative Proteomics.
About Creative Proteomics
Creative Proteomics, as an experienced proteomics, metabolomics, and bioinformatics services supplier, has been well equipped with advanced technologies, in order to meet the increasing needs from researchers and scientists in their proteomics and metabolomics related research.
Contact:
Address: Shirley, NY 11967, USA
Email: contact@creative-proteomics.com
-
Most popular related searches
Related news
-
CD Genomics Fully Supports Your Microbiome Research with Comprehensive Sequencing Solutions
CD Genomics is a leading services company committed to providing global customers with the most comprehensive analytic services, including a broad range of microbial genomic solutions to support research and development. The company announced microbiome profiling services, alongside bioinformatic analysis technology to help researchers understand the significance of human and animal microbiota. Through long-term and detailed studies of the gut microbiota, scientists have revealed the complex relationship...
-
Creative Proteomics Cytokine Announces Cytokine Systemic Lupus Erythematosus Cytokines Assay Solutions
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative proteomics recently announced high sensitivity and wide detection range quantitative detection for systemic lupus erythematosus related cytokines and proteins through a variety of technologies. Systemic lupus erythematosus is a typical systemic autoimmune...
-
Creative Proteomics's Targeted Metabolomic Platform Supports Ketone Body Detection
Creative Proteomics is an experienced outsourcing service provider offering professional and high-quality multi-omics services to academic research institutions and pharmaceutical industry. Creative Proteomics offers targeted metabolomics services for the enrichment and accurate quantitative profiling of a specific metabolite in blood, urine or other body fluids and tissues under specific physiological or pathological conditions. Targeted metabolomics is a qualitative and quantitative analysis method for...
-
Bayer extends clinical development program for finerenone with Phase III study in children and adolescents with chronic kidney disease
For children and adolescents with chronic kidney disease (CKD), as for adults, the unmet need is high for new treatments to delay disease progression and preserve kidney function / The Phase III study FIONA will investigate the effect of finerenone in pediatric patients with CKD and severely increased proteinuria Bayer announced today the initiation of the FIONA study, a multicenter, randomized, double-blind, placebo-controlled Phase III study, to investigate the efficacy, safety and pharmacokinetics/pharmacodynam...
-
New data from finerenone clinical trial program reinforces renal and cardiovascular benefits in patients with CKD and T2D independent of baseline therapy
Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, indicated a reduction in renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as seen in the FIDELIO-DKD study Analysis of the FIDELIO-DKD study highlighted that early reduction of urine albumin-to-creatinine ratio (UACR) with finerenone reduced the risk of cardiovascular events and of disease progression of CKD, underpinning the importance of timely...
Customer comments
No comments were found for Creative Proteomics Offers Untargeted Metabolomics Service for Academia and Various Industries. Be the first to comment!